Xeris Biopharma (XERS) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Zenas BioPharma (ZBIO) over the past year, gaining 24.3% versus a gain of 1.3%. Xeris Biopharma is the larger company by market cap ($1.91 billion vs $1.78 billion), about 1.1 times the size, while Zenas BioPharma is growing revenue faster (+100.0% vs +43.7%). Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -3777.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | XERS | ZBIO |
|---|---|---|
| Share price | $10.49 | $27.24 |
| Market cap | $1.91B | $1.78B |
| 1-day change | +2.89% | +3.81% |
| YTD return | +29.81% | -27.73% |
| 1-year return | +24.27% | +1.31% |
| 5-year return | +409.50% | — |
| Forward P/E | 28.34 | — |
| EPS (TTM) | $-0.10 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $291.85M | $10.00M |
| Revenue growth (YoY) | +43.72% | +100.00% |
| Net income (latest FY) | $554.00K | $-377.74M |
| Gross margin | 85.41% | — |
| Operating margin | 8.53% | -3830.57% |
| Net margin | 0.19% | -3777.37% |
| 52-week high | $11.33 | $44.60 |
| 52-week low | $5.25 | $13.50 |
| Distance from 52-week high | -7.46% | -38.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +22.65% | +75.77% |
| Average volume | 2.17M | 733.34K |
| Shares outstanding | 182.32M | 65.18M |
| Employees | 435 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed ZBIO by 23.0 percentage points over the past year.
- Xeris Biopharma is more profitable, keeping 0.2 cents of every revenue dollar as net income versus -3777.4 cents for Zenas BioPharma.
- Zenas BioPharma grew revenue faster in its latest fiscal year (+100.00% vs +43.72%).
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
XERS vs ZBIO FAQ
Which is bigger, Xeris Biopharma or Zenas BioPharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $1.91B compared with $1.78B for Zenas BioPharma (ZBIO).
Which stock has performed better over the past year, XERS or ZBIO?
XERS returned +24.27% over the past 12 months, compared with +1.31% for ZBIO (price return, excluding dividends). Past performance does not predict future results.
Are Xeris Biopharma and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.